WHO Register of non-State actors

Disclaimer:

Information regarding a non-State actor, contained in the section “Non-State Actors Profiles” in the Register, has been provided by that non-State actor itself, and the accuracy and completeness of such information is the sole responsibility of that non-State actor, not WHO. In turn, information in the sections “WHO’s Engagement” and “Non-State Actors in Official Relations” has been provided by WHO, subject to certain conditions. All access and use of any section of the Register is governed by the Terms and Conditions of Use.

Overview

Official name

Health Technology Assessment international

Acronym (if applicable)

HTAi

Short self description

Health Technology Assessment international (HTAi) is the global scientific and professional society for all those who produce, use, or encounter Health Technology Assessments (HTAs). HTAi has members from over 80 organisations across 65 countries. We are the neutral forum for collaboration and the sharing of leading information and expertise specifically related to HTA. Stakeholders including researchers, agencies, policy makers, industry, academia, health service providers, and patients/consumers come together to drive our field.

Website

http://htai.org

Web link to health relevant activities

Parent entity (if applicable)

The entity you represent is indicated as a parent of the following entities in the Register:

N / A

Date submitted

20 Nov 2023 08:47:46 PM

General information

Name

Official name

Health Technology Assessment international

Acronym (if applicable)

HTAi

Commonly used name (if applicable)

Names in other official languages (if applicable) Name Abbreviation

Health Technology Assessment International

HTAi

Former name

Short self description

Address Contact

Address 1

1280, 5555 Calgary Trail

Address 2

Address 3

Town/City

Edmonton

State/Region

Alberta

Postal code

T6H 5P9

Country

Canada

Email (generic)

info@htai.org

Related links

Website

http://htai.org

Governance

Legal status

Non-Profit | Charitable Organization No. 861373306RR0001

Year established

2004

Governance structure

Description of main decision making bodies (e.g. board, board of directors, executive board, executive committee, etc).

Name of body

Board of Directors

Composition and current list of members Name Function Affiliation

Rabia Sucu

President

Management Sciences for Health, USA

Ann Single

Vice-President

Singlehaworth Pty Ltd.

Jo Carol Hiatt

Secretary

Medical Device Innovation Consortium

Americo Cicchetti

Treasurer

Università Cattolica del Sacro Cuore, Faculty of Economics

Debjani Mueller

Director

University of Pretoria

Ken Bond

Director

Institute of Health Economics, Canada

Wim Goettsch

Director

Dutch National Health Care Institute

Wija Oortwijn

Past President

Radboud University Medical Centre

Dimitra Lingri

Director

European Fraud and Corruption Network

Marco Marchetti

Director

National Agency For Regional Health Services

Eva Turk

Director

University of Applied Sciences St.Pölten

Grace Huang

Director

Center for Drug Evaluation, Taiwan, China

Functions

The Board of Directors shall, subject to the Bylaws or directions given by a majority vote at any general meeting of the Society properly called and constituted:

a) have full control and management of the affairs of the Society; and

b) have the power to adopt or amend policy, guidelines, procedures or regulations, by motion passed by the majority of the Board at any Board of Directors Meeting, which shall be binding upon all members of the Society.

Name of body

Executive Committee

Composition and current list of members Name Function Affiliation

Rabia Sucu

President

Management Sciences for Health, USA

Ann Single

Vice-President

Singlehaworth Pty Ltd.

Jo Carol Hiatt

Secretary

Medical Device Innovation Consortium

Americo Cicchetti

Treasurer

Università Cattolica del Sacro Cuore, Faculty of Economics

Functions

1. Making decisions on behalf of the Board on emerging issues arising between full
Board meetings and communicating the decisions to the Board.
2. Proposing needed changes to the Bylaws, for consideration by the Board.
3. Reviewing existing and developing new policies and procedures and making
recommendations to the Board of Directors.
4. Reviewing the agenda for Board meetings; and, in collaboration with the
President and Secretariat, ensuring relevant background material is provided to
support Board’s decision-making.
5. Overseeing the planning and conducting of the Annual General Meetings (AGM).
6. Authorizing the Secretariat to conduct negotiations with external parties on behalf
of the Society.
7. Overseeing Board annual self-evaluations.
8. Ensuring that HTAi committees have their full complement of members, and
directly appointing members as and when needed to ensure the effective
operation of said committees.
9. Reviewing the HTAi committee structure as needed and making
recommendations to the Board for improvements in this regard.
10. Reviewing existing Terms of Reference and developing Terms of Reference for
any new committees established by the Board of Directors and making
recommendations to the Board.
11. Reviewing the need to establish working groups and/or task forces with likeminded organizations in HTA field to work on a single defined task or activity,
developing their Terms of Reference, and making recommendations to the
Board.
12. Reviewing the nominations for the David Banta Award in consultation with the
two most recent Past Presidents and making a decision to bestow the Award in
any given year.
13. Providing appropriate orientation and development for new and returning
Directors

General Assembly

Does the entity have a General Assembly of members or a similar body?

Yes

Name

General Meeting of Members

Composition

All members of the organization

Functions

The appointment of the Auditor, the presentation of the financial statement, and other business matters of the Society shall be discussed at the Annual General Meeting.

Financial information

Latest available annual income (month/year)

From

January

2022

December

2022

Annual income (USD)

2,294,943

Latest available assets (month/year)

As of

December

2022

Total assets (USD)

2,988,959

Income sources (in USD)

Income source Income type

Private sector entities (including business associations)

Philanthropic foundations

NGOs, academic institutions

Government entities, intergovernmental organizations, including UN

General public, individuals

Total

Sales of goods and services *

887,489

Grants / Donations

In-kind donations

Membership fees

1,107,900

105,172

7,586

58,585

1,279,243

Investment income

33,466

Others

94,745

Total

1,107,900

105,172

7,586

1,074,285

2,294,943

* income from congresses / conferences should be listed under Sales of goods and services

Additional information

Sale of goods and services includes all annual meeting revenue and sponsorships for events.

Membership

Entity's members

Is the entity you represent membership based?

Yes

Overview of categories and their voting rights in the main governing body:

Total number Voting

Individuals

490

NGOs

Private sector entities

Philanthropic foundations

Academic institutions

Government entities

Intergovernmental organizations

Organizational Structure

Parent entity

In the register Registered Entity Entity Name

No data available

Yes

Legal status

Affiliated entities (or subsidiaries)

In the register Registered Entity Entity Name

No data available

Relations

Entity's membership in other entities

In the register Registered Entity Entity Name Type of membership

No data available

Members of the entity

In the register Registered Entity Member Name

No data available

Activities

Aims (or purposes, objectives) of the entity as they appear in its constitution or by-laws or equivalent document.

HTAi supports and promotes the development, communication, understanding, and use of HTA around the world as a scientifically-based and multidisciplinary means of informing decision-making on the use of safe and effective technologies and the efficient use of resources in health care.

The activities of the entity are related to the following strategic priorities and outcomes of the current WHO's General Programme of Work:

Strategic Priority 1: One billion more people benefiting from universal health coverage

Outcome 1.1 - improved access to quality essential health services

Outcome 1.2 - reduced number of people suffering financial hardships

Outcome 1.3 - improved access to essential medicines, vaccines, diagnostics and devices for primary health care

Strategic Priority 2: One billion more people better protected from health emergencies

Outcome 2.1 - countries prepared for health emergencies

Outcome 2.2 - epidemics and pandemics prevented

Outcome 2.3 - health emergencies rapidly detected and responded to

Strategic Priority 3: One billion more people enjoying better health and well-being

Outcome 3.1 - determinants of health addressed

Outcome 3.2 - risk factors reduced through multisectoral action

Outcome 3.3 - healthy settings and Health in All Policies promoted

Strategic Priority 4: More effective and efficient WHO providing better support to countries

Outcome 4.1 - strengthened country capacity in data and innovation

Additional information on the entity's activities

Health Economics, Health Promotion, Health Legislation, Medical technology, Ethcis and health, Health Care administration

Country presence

Countries where the entity has activities, members and regional offices / representatives:

Regions

Countries

Activities

Members

Offices / representatives

African Region

Region of the Americas

Eastern Mediterranean Region

European Region

South-East Asia Region

Western Pacific Region

Global

Disclosure & declaration

Tobacco/Arms related disclosure statement for non-State actors

Pursuant the WHO Framework of Engagement with Non-State Actors, WHO does not engage with the tobacco industry or non-State actors that work to further the interests of the tobacco industry. WHO also does not engage with the arms industry.

For the purposes of this statement:

tobacco industry means any entity involved in the manufacture, sale or distribution of tobacco and related products, and any affiliate of such entity; and
arms industry means any entity involved in the manufacture, sale or distribution of arms, and any affiliate of such entity.

This disclosure statement needs to be provided by any nongovernmental organization, private sector entity, philanthropic foundation and academic institution prior to engaging with WHO.

In view of the foregoing, please answer the following questions:

Is your entity, or was your entity over the last four years, part of the tobacco or arms industries (as defined above)?

Yes

No

Unable to answer

To the best of your entity’s knowledge, is your entity, or has your entity over the last four years, engaged in activities that are aimed at furthering or supporting the interests of the tobacco industry? This includes, but is not limited to, supply contracts, contract work, services and lobbying.

Yes

No

Unable to answer

To the best of your entity’s knowledge, does your entity currently, or did your entity over the last four years, have any other association or relationship with the tobacco industry (as defined above). This includes in particular investment interests (other than general mutual funds or similar arrangements whereby your entity has no control over the selection of the investments), commercial business interests, the provision or receipt of financial and/or other support.

Yes

No

Unable to answer

If you have answered yes to any of the above or are unable to answer one or more questions, please provide a general statement of explanation.

Please note that the WHO Secretariat reserves the right to request additional information from your entity in this regard.

By providing this statement, your entity commits to promptly inform WHO of any change to the above information and to complete a new statement that describes the changes.

Engagement with other industries affecting human health or affected by WHO norm and standards

Does the entity you represent have any formal association, affiliation or links with the following industry sectors?

If yes, please tick the box of the industry concerned and provide details in the space provided:

Alcohol

Chemical

Food and beverages

Health care

Pharmaceutical

Others

Please specify industry

Health Technologies (Healthcare, Biotech, Pharmaceutical)

International Network of Agencies for Health Technology Assessment
HTA Glossary
EuroScan
HTAsiaLink
AMGEN (Europe) GmbH
Becton Dickinson Holdings Pte LTd.
Biomarin
Boston Scientific Corporation
Edwards Lifesciences Corp
Eli Lilly and Company
F. Hoffmann-La Roche AG
Genzyme Corporation (Sanofi)
GlaxoSmithKline
Johnson & Johnson Services Inc.
Medtronic Inc.
Merck & Co
Novartis Pharmaceuticals Corporation
Pfizer Inc.
Pfizer Corporation Hong Kong Ltd.
Takeda Pharmaceutical Company Limited
ViewRay, Inc.
Org members
Abbott Vascular International BVBA
Adelaide Health Technology Assessment
Agenzia Sanitaria e Sociale Regionale
AHRQ, Center for Outcomes and Evidences
Alberta Health Services
All Wales Therapeutics & Toxicology Center
AMGEN (Europe) GmbH
Angelini SPA
AQuAS
Astellas Pharma
AstraZeneca UK Ltd
Australian Government, PBAC and MSAC
Avalia-t
BioMarin International Ltd.
Blue Cross Blue Shield Association
Boston Scientific Corporation
Bristol Myers Squibb Co.
CADTH
CEEBM FMUI-CMH
Center for Medical Technology Policy
Center for Outcomes and Res. EEH. C2H
Centre for Community-Driven Research
Changi General Hospital
CONITEC
Dental and Pharmaceutical Benefits Agency
Edwards Lifesciences Corp
Effective Basic Services
Eli Lilly and Company
F. Hoffmann-La Roche AG
Finnish Coordinating Center for HTA
Genzyme Corporation (Sanofi)
Gilead Sciences, Inc.
GlaxoSmithKline
Haute Authorite de Santé
Health Information and Quality Authority
Health Quality Ontario
Health Technology Assessment Association
Health Technology Wales
Healthcare Improvement Scotland
HTA Skane
INASanté
Institute for Clinical & Economic Review
Institute of Health Economics
Instituto Aragonés de Ciencias
IQVIA Commercial GmbH & Co OHG
IQWiG
Johnson & Johnson Services Inc.
Kaiser Permanente Inc.
Kazakh Agency for Health
Medtronic Inc.
Merck & Co
Merck KGaA
Ministry of Health Malaysia
Ministry of Health, Republic of Turkey
National Center For Expertise of Medicine
National Institute for Health and Care Excellence, UK
National Institute for Health and Care Research Innovation Observatory (NIHRIO), The University of Newcastle upon Tyne
Norwegian Centre for E-health Research
Norwegian Institute of Public Health
Novartis Pharma AG
Australian Commission on Safety and Quality in Health Care
OSTEBA, Ministry of Health, Basque Gov
Patient-Centered Outcomes Research Institute, Washington, DC, USA
Pfizer Inc.
Republican Centre for Health Development
SBU Swedish Agency for HTA
Swiss Federal Office of Public Health
Takeda Pharmaceutical Company Limited
Uganda Academy for Health Innovation
ViewRay, Inc.
W.L. Gore & Associati S.r.l.
Zorginstitut Nederland

WHO Secretariat reserves the right to request additional information from the entity you represent relevant to its engagement with WHO.

*Sexual Exploitation, Abuse and Harassment (SEAH) and Misconduct (abusive or fraudulent)

Entities engaging with WHO are expected to ensure that the conduct of their employees and any other persons engaged by them to perform any activities or to provide any services for WHO on behalf of the entities is consistent with the WHO standards of conduct. In particular, WHO has zero tolerance towards any form of sexual misconduct, which includes sexual exploitation, sexual abuse, sexual violence, and sexual harassment, and other types of abusive or fraudulent conduct. In the view of the forgoing, please confirm that your entity shall:

Take all reasonable and appropriate measures to prevent sexual misconduct as defined in WHO’s Policy on Preventing and Addressing Sexual Misconduct, and other types of abusive or fraudulent conduct as defined, respectively, in WHO’s Policy on Preventing and Addressing Abusive Conduct and in WHO’s Policy on Prevention, Detection and Response to Fraud and Corruption by any of its employees and by any other persons engaged by it to perform any activities or to provide any services for WHO on the entity’s behalf;

Promptly report to WHO’s Office of Internal Oversight Services (IOS) at investigation@who.int any actual or suspected misconduct, as defined by WHO in these Policies and of which the entity becomes aware;

Promptly communicate to IOS any measures that may be necessary or appropriate to protect the confidentiality and wellbeing of the alleged victim;

Promptly respond to any actual or suspected misconduct as defined by WHO in these Policies of which the entity becomes aware; and

To cooperate with IOS and keep IOS informed of the status and outcome of any measures of protection, corrections to operations, investigation, and disciplinary action taken against any perpetrator by the entity.

Date submitted